Literature DB >> 19414394

Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer.

Subhani M Okarvi1, Ibrahim A Jammaz.   

Abstract

HER2/neu and MUC1-based synthetic peptides were prepared and evaluated in an effort to develop peptide-based radiopharmaceuticals derived from tumor-associated-antigens for the detection of breast cancer. The receptors for HER2/neu and MUC1 are overexpressed in various human cancers, such as breast and ovarian cancer. The relatively low expression of these antigens on normal tissues makes them attractive targets for tumor imaging. In addition, antitumor-antibody-derived peptides based on the Glu-Pro-Pro-Thr (EPPT) sequence were prepared for the detection of breast cancer. It has been shown that the EPPT peptide has high affinity for the MUC1-derived peptide. The peptides were prepared by solid-phase synthesis and radiolabeled efficiently with (99m)Tc via ligand exchange. They exhibited good stability in vitro in human plasma and against cysteine and histidine challenge. The peptides displayed high affinities (in nanomolar range) for MCF-7, MDA-MB-231 and T47-D breast cancer cell lines in vitro. Additionally, they exhibited a rapid internalization into tumor cells. In vivo biodistribution in mice showed rapid and efficient blood clearance and excretion mainly through the renal-urinary route, with some elimination via the hepatobiliary pathway. However, the extent of urinary excretion was found to be variable for radiopeptides, with the highest being observed for antitumor-antibody-derived peptide. The peptides showed moderate tumor uptake (up to 2.2+/-0.98% ID/g) in nude mice carrying breast tumor xenografts. The uptake in the tumor was always higher than in the blood and muscle. A fast clearance from the blood and low accumulation (<6% ID/g) by the major organs was obtained in nude mice resulting in favorable tumor/blood and tumor/muscle ratios as early as 1 h after injection. The combination of favorable in vitro and in vivo characteristics makes this new and interesting class of peptides potential candidates for the diagnosis of breast cancer in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414394

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Antibody recognition of a unique tumor-specific glycopeptide antigen.

Authors:  Cory L Brooks; Andrea Schietinger; Svetlana N Borisova; Peter Kufer; Mark Okon; Tomoko Hirama; C Roger Mackenzie; Lai-Xi Wang; Hans Schreiber; Stephen V Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 2.  Peptide-mediated cancer targeting of nanoconjugates.

Authors:  Sumita Raha; Tatjana Paunesku; Gayle Woloschak
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-11-02

Review 3.  Gastrin-releasing peptide links stressor to cancer progression.

Authors:  Xinqiu Li; Yunfu Lv; Aihua Yuan; Zongfang Li
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-06       Impact factor: 4.553

4.  Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool.

Authors:  Marleen van Oosten; Lucia Ma Crane; Joost Bart; Fijs W van Leeuwen; Gooitzen M van Dam
Journal:  Transl Oncol       Date:  2011-04-01       Impact factor: 4.243

5.  Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma.

Authors:  I Al Jammaz; B Al-Otaibi; Y Al-Malki; A Abousekhrah; S M Okarvi
Journal:  EJNMMI Radiopharm Chem       Date:  2021-03-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.